Kenvue stock sinks to record low as Trump to reportedly link Tylenol use to autism

Kenvue stock plummeted 7.1% to a record low following reports that former President Trump plans to announce a link between Tylenol use in pregnancy and autism, a claim Kenvue strongly refutes, citing independent science. This reported announcement, which contradicts decades of medical guidance and has sparked a polarizing scientific debate among researchers, presents significant legal and reputational challenges for the J&J spin-off, potentially increasing consumer mistrust and its existing legal liabilities despite Tylenol being widely considered safe for expectant mothers.

Analysis

Kenvue Inc. (KVUE) shares experienced a significant sell-off, falling 7.1% to a record low of $17.03, following reports of a planned U.S. government announcement linking its top-selling product, Tylenol, to autism risk when used during pregnancy. This political development, which contradicts decades of established medical guidance, has made Kenvue the worst performer in the S&P 500 and amplified a stock slump that began earlier in the month. The company has strongly refuted the claims, citing scientific evidence that shows no causal link. The controversy highlights a polarized scientific debate: while some smaller reviews suggest a potential connection, a large-scale Swedish study of 2.5 million children found no association, and international health bodies like the UK's NHS continue to recommend acetaminophen as safe. This event creates a material headwind for Kenvue, which was spun out of Johnson & Johnson in 2023, by exposing it to heightened reputational damage, potential consumer mistrust, and an escalation of legal risk, as it already faces state-level lawsuits on the matter.

Key Decisions for Investors

• Investors should brace for continued high volatility in KVUE stock, as its price will be highly sensitive to political announcements and media sentiment, regardless of the underlying scientific evidence.
• Closely monitor developments in existing and potential new state-level lawsuits, as an increase in litigation tied to this announcement represents a significant and unquantified financial liability for the company.
• Analyze near-term sales data for Tylenol and generic acetaminophen to gauge the actual impact on consumer behavior, as sustained brand erosion would directly threaten a core revenue stream.
• For risk-tolerant investors, the sharp divergence between the politically-driven stock price and the prevailing scientific consensus may present a contrarian opportunity, contingent on consumer trust in Tylenol proving resilient over the long term.